Addressing the therapeutic constraints associated with single-antigen CD19-directed CAR-T approaches in refractory B-cell neoplasms, Zhou et al. presented a novel trispecific NbCAR-T (LCAR-AIO) targeting CD19, CD20, and CD22. This evidence concerns the gene CD19 and B-cell neoplasm.